COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children

COG NCTN 儿童造血系统恶性肿瘤综合转化科学中心

基本信息

批准号：
10117202
负责人：
SOHEIL MESHINCHI
金额：
$ 80万
依托单位：
CHILDREN'S HOSP OF PHILADELPHIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-18 至 2022-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10117202
关键词：
Acute Lymphocytic Leukemia Acute Myelocytic Leukemia Acute Promyelocytic Leukemia Address Adult Area B-Lymphocytes Biological Biological Markers Biological Sciences Biology Cancer Biology Cancer Etiology Cancer Survivor Cause of Death Center for Translational Science Activities Child Child Care Child Support Childhood Childhood Leukemia Classification Clinic Clinical Clinical Research Clinical Trials Clinical Trials Cooperative Group Cytotoxic Chemotherapy Data Developmental Therapeutics Program Diagnostic Disease Elements Ensure Eosinophilic Granuloma Evaluation Fostering Funding Generations Genomic approach Genomics Goals Grant Guidelines Hematologic Neoplasms Hematopoietic Hematopoietic Neoplasms Heterogeneity Hodgkin Disease Infrastructure Intervention Juvenile Myelomonocytic Leukemia Laboratories Leadership Link Malignant Childhood Neoplasm Malignant Neoplasms Microscopy Molecular Morphology Multi-Institutional Clinical Trial Non-Hodgkin&apos s Lymphoma North America Outcome Patients Pediatric Neoplasm Pediatric Oncology Group Phase Pilot Projects Quality of life Relapse Research Research Project Grants Resources Risk Solid Specimen Structure Survivors T-Lymphocyte Therapeutic Therapeutic Intervention Therapeutic Trials Therapeutic Uses Translating Translational Research Translations Treatment Efficacy Validation Variant base childhood cancer mortality clinical application clinical implementation clinical practice clinically actionable clinically relevant design epigenomics fundamental research improved improved outcome innovation leukemia/lymphoma molecular diagnostics molecular marker new therapeutic target novel novel marker operation outcome prediction personalized approach pre-clinical prevent programs prospective research study risk stratification statistics success targeted treatment therapeutic development therapeutic target young adult

项目摘要

Project Summary Hematopoietic malignancies including leukemias and lymphomas contribute to nearly half of all cancers and are a major cause of death from disease in children. The Children’s Oncology Group (COG) has spearheaded efforts to improve outcome in children with cancer, and despite dramatic improvements in survival over the last several decades, relapse remains a major problem, and survivors may suffer long term complications from the cytotoxic therapy. Better understanding of the biology of malignancies allows for more rational, targeted approaches to therapy, minimizing the need or the intensity of the non-selective cytotoxic therapies. Such targeted approaches have transformed some diseases from uniformly fatal to highly curable ones (e.g., CML, APL), but a paucity of actionable targets has prevented broader application of targeted interventions in hematopietic malignancies. As part of its focus on optimizing the survival in pediatric cancers and improving quality of life for the cancer survivors, COG through partnerships with NCI has conducted a number of discovery phase studies to identify the biologic basis of cancer in children, with the goal of identifying specific targets for more appropriate risk stratification and directed therapies in its clinical trials. With the emerging data from pediatric (and adult) discovery phase studies, COG is poised to take the next step in identifying actionable targets for therapeutic intervention. As part of these efforts, COG has created the Network Group Integrated Translational Science Centers (ITSCs) aimed at providing resources for therapeutically driven translational research. COG Hematopoietic ITSC (HM-ITSC) has put into place intellectual (leadership) and physical resources (resource laboratories, biospecimens, etc.) to ensure rapid identification of actionable targets through carefully designed translational research projects, and fostering the experimental data through a carefully structured mechanism to clinical application. HM-ITSC is structured and integrated into the functional operations of the COG, with direct links to the COG Operations Office, Disease Committees, Network group Data and Statistics Center and Developmental Therapeutics in order to facilitate rapid flow of actionable translational biology data to clinical implementation within NCTN clinical trials. Hematopoietic Malignancies (HM) are a major cause of cancer in children and novel therapeutic targets are needed to optimize outcome. COG HM-Integrated Translational Science Center, integrated into the functional organization of COG, will provide resources to support translational research in pediatric leukemias and lymphomas towards identification of clinically meaningful targets and their incorporation into clinical trials.

项目概要包括白血病和淋巴瘤在内的造血系统恶性肿瘤占所有癌症的近一半是儿童疾病死亡的一个主要原因。改善患有癌症的儿童的治疗结果，尽管过去的生存率有了显着提高几十年来，复发仍然是一个主要问题，幸存者可能会遭受长期并发症。更好地了解恶性肿瘤的生物学特性可以使治疗更加合理、更有针对性。治疗方法，最大限度地减少非选择性细胞毒性治疗的需要或强度。有针对性的方法已将一些疾病从一贯致命的疾病转变为高度可治愈的疾病（例如慢性粒细胞白血病、 APL），但由于缺乏可操作的目标，阻碍了有针对性的干预措施的更广泛应用作为其重点优化儿科癌症生存和改善的一部分。为了提高癌症幸存者的生活质量，COG 通过与 NCI 合作开展了一系列活动发现阶段研究旨在确定儿童癌症的生物学基础，目标是确定特定的随着新数据的出现，目标是在临床试验中进行更合适的风险分层和定向治疗。根据儿科（和成人）发现阶段的研究，COG 准备采取下一步行动，确定可行的措施作为这些努力的一部分，COG 创建了综合网络组。转化科学中心（ITSC）旨在为治疗驱动的转化提供资源 COG 造血 ITSC (HM-ITSC) 已将智力（领导力）和体力落实到位。资源（资源实验室、生物样本等），以确保快速识别可操作的目标通过精心设计的转化研究项目，并通过 HM-ITSC 的结构经过精心构建，并融入到功能中。 COG 的运作，与 COG 运作办公室、疾病委员会、网络小组有直接联系数据和统计中心以及发展治疗学，以促进可操作的快速流动 NCTN 临床试验中的转化生物学数据到临床实施。（HM）是儿童癌症的主要原因，需要新的治疗靶点来优化结果。 COG HM-综合转化科学中心，整合到COG的职能组织中，将提供资源支持儿科白血病和淋巴瘤的转化研究识别具有临床意义的目标并将其纳入临床试验。